Otitis Media - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Otitis Media - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Otitis Media - Pipeline Review, H1 2016', provides an overview of the Otitis Media pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Otitis Media
- The report reviews pipeline therapeutics for Otitis Media by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Otitis Media therapeutics and enlists all their major and minor projects
- The report assesses Otitis Media therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Otitis Media

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Otitis Media
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Otitis Media Overview 8
Therapeutics Development 9
Pipeline Products for Otitis Media - Overview 9
Pipeline Products for Otitis Media - Comparative Analysis 10
Otitis Media - Therapeutics under Development by Companies 11
Otitis Media - Therapeutics under Investigation by Universities/Institutes 12
Otitis Media - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Otitis Media - Products under Development by Companies 16
Otitis Media - Products under Investigation by Universities/Institutes 17
Otitis Media - Companies Involved in Therapeutics Development 18
Cellceutix Corporation 18
ContraFect Corporation 19
GlaxoSmithKline Plc 20
Lee's Pharmaceutical Holdings Limited 21
Merck & Co., Inc. 22
MerLion Pharmaceuticals Pte Ltd 23
Oticpharma Ltd 24
Otonomy, Inc. 25
Yuhan Corporation 26
Otitis Media - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
betahistine hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
brilacidin tetrahydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CF-309 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ciprofloxacin hydrochloride SR - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ciprofloxacin hydrochloride SR - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
finafloxacin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GSK-2189242A - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pazufloxacin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PCL-1402 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
solithromycin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
YH-1177 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Otitis Media - Recent Pipeline Updates 54
Otitis Media - Dormant Projects 75
Otitis Media - Product Development Milestones 77
Featured News & Press Releases 77
Dec 11, 2015: Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery 77
Nov 03, 2015: Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients with History of Otitis Media Requiring Tympanostomy Tubes 77
Sep 24, 2015: Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting 78
May 07, 2015: Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes 78
Apr 28, 2015: Otonomy Announces FDA Acceptance of AuriPro New Drug Application 79
Apr 27, 2015: Otonomy Presents AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference 79
Apr 21, 2015: Otonomy to Present AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference 80
Mar 26, 2015: Otonomy Initiates Phase 2 Clinical Trial for AuriPro in Label Expansion Indication 80
Feb 26, 2015: Otonomy Submits New Drug Application to the FDA for AuriPro 80
Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables

Number of Products under Development for Otitis Media, H1 2016 9
Number of Products under Development for Otitis Media - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Otitis Media - Pipeline by Cellceutix Corporation, H1 2016 18
Otitis Media - Pipeline by ContraFect Corporation, H1 2016 19
Otitis Media - Pipeline by GlaxoSmithKline Plc, H1 2016 20
Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 21
Otitis Media - Pipeline by Merck & Co., Inc., H1 2016 22
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2016 23
Otitis Media - Pipeline by Oticpharma Ltd, H1 2016 24
Otitis Media - Pipeline by Otonomy, Inc., H1 2016 25
Otitis Media - Pipeline by Yuhan Corporation, H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Otitis Media Therapeutics - Recent Pipeline Updates, H1 2016 54
Otitis Media - Dormant Projects, H1 2016 75
Otitis Media - Dormant Projects (Contd..1), H1 2016 76